445 MARINE VIEW AVE SUITE 320, DEL MAR, CA
Other Events
Announces Commercial Product Availability of VIZZ in the United States
Announces US FDA Approval of VIZZ TM for the Treatment of Presbyopia
Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Shareholder votes
Earnings Release
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement